Education
About Us
Working with TipRanks
Follow Us
Open Orphan Plc (GB:HVO)
:HVO
HVO Stock Chart & Stats
Day’s Range― - ―
52-Week Range6.36p - 30.00p
Previous CloseN/A
Volume5.15K
Average Volume (3M)2.16M
Market Cap
£45.34M
Enterprise Value109.63M
Total Cash (Recent Filing)£44.18M
Total Debt (Recent Filing)£12.90M
Price to Earnings (P/E)4.2
Beta-0.26
Next Earnings
Apr 15, 2026EPS EstimateN/A
Last Dividend Ex-Date
May 15, 2025Dividend Yield2.9%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding687,014,100
10 Day Avg. Volume3,059,613
30 Day Avg. Volume2,158,424
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£23.00Price Target Upside248.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Business StrategyManagement has executed its strategy to diversify the business, which positions hVIVO to deliver its medium-term growth ambitions as a growing CRO.
EarningsThe integration of recent acquisitions CRS and Cryostore is progressing as planned, which is expected to positively impact the company's future revenues.
Stock ValuationThe current share price is seen as an attractive entry point, particularly on a multi-year view, indicating potential for future gains.
Bears Say
Contract ConversionThe market remains focused on the need for further conversion of new contracts to build revenue cover as 2025 progresses, indicating a potential risk if not addressed.
Funding EnvironmentThe continued tight biotech funding environment was highlighted as the primary headwind, versus wider market concerns.
Open Orphan Plc News
HVO FAQ
What was Open Orphan Plc’s price range in the past 12 months?
Open Orphan Plc lowest share price was 6.36p and its highest was 30.00p in the past 12 months.
What is Open Orphan Plc’s market cap?
Open Orphan Plc’s market cap is £45.34M.
When is Open Orphan Plc’s upcoming earnings report date?
Open Orphan Plc’s upcoming earnings report date is Apr 15, 2026 which is in 188 days.
How were Open Orphan Plc’s earnings last quarter?
Open Orphan Plc released its earnings results on Sep 23, 2025. The company reported 0.003p earnings per share for the quarter, beating the consensus estimate of N/A by 0.003p.
Is Open Orphan Plc overvalued?
According to Wall Street analysts Open Orphan Plc’s price is currently Undervalued.
Does Open Orphan Plc pay dividends?
Open Orphan Plc pays a Annually dividend of 0.2p which represents an annual dividend yield of 2.9%. See more information on Open Orphan Plc dividends here
What is Open Orphan Plc’s EPS estimate?
Open Orphan Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Open Orphan Plc have?
Open Orphan Plc has 687,014,100 shares outstanding.
What happened to Open Orphan Plc’s price movement after its last earnings report?
Open Orphan Plc reported an EPS of 0.003p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -7.778%.
Which hedge fund is a major shareholder of Open Orphan Plc?
Currently, no hedge funds are holding shares in GB:HVO
Open Orphan Plc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
£23.00 (248.48% Upside)
£23.00 (248.48% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.50%
12-Months-Change
Fundamentals
Return on Equity
26.97%
Trailing 12-Months
Asset Growth
6.81%
Trailing 12-Months
Company Description
Open Orphan Plc
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides preclinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.
HVO Stock 12 Month Forecast
Average Price Target
23.00p
▲(248.48% Upside)
Technical Analysis
Avacta Group plc
―
Scancell Holdings
―
SkinBioTherapeutics
―
4basebio UK Societas
―
Ondine Biomedical, Inc.
―
Options Prices
Currently, No data available
---